Abuse Potential of Carisoprodol: A Retrospective Review of Idaho Medicaid Pharmacy and Medical Claims Data

Owens, Christopher; Pugmire, Brooke; Salness, Ty; Culbertson, Vaughn L.; Force, Rex W.; Cady, Paul S.; Steiner, Joseph F.

doi:10.1016/j.clinthera.2007.10.003

Cited by 14 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, on day 21, the average oxycodone dose for persons using muscle relaxants at baseline was 21.7 mg (± 18.5) compared with 18.2 mg (± 24.4) in those not reporting muscle relaxant use at baseline. While there is concern about the use of muscle relaxants and opioids simultaneously, for example others have shown increased likelihood of use of muscle relaxants with worsening pain . A recent study in healthy volunteers suggests potential synergistic effects between carisopordol and oxycodone .…”

Section: Discussionmentioning

confidence: 99%

Impact of Noncancer Pain on Health‐Related Quality of Life

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Noncancer Pain on Health‐Related Quality of Life

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Carisoprodol is a centrally acting muscle relaxant used for acute back pain [1] that has been on the market for almost 50 years [2]. Numerous publications report abuse [3][4][5][6][7][8][9][10][11][12] and deaths attributed to the drug [13][14][15] and we have previously published studies showing that carisoprodol is a frequently detected drug in cases of driving under the influence (DUI) [16][17][18], in forensic autopsies [19] and in contacts to the National Poisons Information Centre (NPIC) in Norway [20].…”

mentioning

confidence: 99%

The Effect of Scheduling and Withdrawal of Carisoprodol on Prevalence of Intoxications with the Drug

Høiseth

Karinen

Sørlid

et al. 2009

Basic Clin Pharma Tox

View full text Add to dashboard Cite

The centrally acting muscle relaxant carisoprodol has previously been shown to cause psychomotor impairment and to have a narrow therapeutic range. In Norway, carisoprodol was therefore reclassified to the highest scheduling level During the same period, the sales figures for carisoprodol decreased dramatically, and we observed a relation between the numbers of DUI cases, forensic autopsies and contacts to the NPIC concerning carisoprodol and the sales figures for the drug. This study showed that the rescheduling and withdrawal of carisoprodol from the Norwegian market had a positive effect on the prevalence of carisoprodol in impaired driving, deaths and contacts regarding intoxications. This, together with previous publications, indicates that the population reflected in our data uses regularly prescribed carisoprodol and, to a lesser degree, drug from an illegal street market.

show abstract

“…“Overlap” variables indicate that a patient is receiving multiple prescriptions for controlled substances that may be concurrent (opioid-opioid, opioid-benzodiazepine, opioid-benzodiazepine-carisoprodol) [4,16,19,25,26,31]. Such patients may be at greater risk due to pharmacokinetic or pharmacodynamic interactions, or high cumulative opioid dose [31].…”

Section: Methodsmentioning

confidence: 99%

High-risk prescribing and opioid overdose: prospects for prescription drug monitoring program–based proactive alerts

Geissert

Hallvik

Otterloo

et al. 2017

PAIN

View full text Add to dashboard Cite

To develop a simple, valid model to identify patients at high risk of opioid overdose-related hospitalization and mortality, Oregon prescription drug monitoring program, Vital Records, and Hospital Discharge data were linked to estimate 2 logistic models; a first model that included a broad range of risk factors from the literature and a second simplified model. Receiver operating characteristic curves, sensitivity, and specificity of the models were analyzed. Variables retained in the final model were categories such as older than 35 years, number of prescribers, number of pharmacies, and prescriptions for long-acting opioids, benzodiazepines or sedatives, or carisoprodol. The ability of the model to discriminate between patients who did and did not overdose was reasonably good (area under the receiver operating characteristic curve = 0.82, Nagelkerke R = 0.11). The positive predictive value of the model was low. Computationally simple models can identify high-risk patients based on prescription history alone, but improvement of the predictive value of models may require information from outside the prescription drug monitoring program. Patient or prescription features that predict opioid overdose may differ from those that predict diversion.

show abstract

Abuse Potential of Carisoprodol: A Retrospective Review of Idaho Medicaid Pharmacy and Medical Claims Data

Cited by 14 publications

References 15 publications

Impact of Noncancer Pain on Health‐Related Quality of Life

Impact of Noncancer Pain on Health‐Related Quality of Life

The Effect of Scheduling and Withdrawal of Carisoprodol on Prevalence of Intoxications with the Drug

High-risk prescribing and opioid overdose: prospects for prescription drug monitoring program–based proactive alerts

Contact Info

Product

Resources

About